Cargando…

Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study

BACKGROUND: Observational studies have shown that excessive dietary fat may be associated with lung carcinogenesis. However, findings from previous studies are inconsistent and it remains unclear whether docosapentaenoic acid (DPA), a kind of polyunsaturated fatty acid, is linked to the risk of lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jiaqing, Zhou, Huaqiang, Zhang, Yaxiong, Huang, Yan, Fang, Wenfeng, Yang, Yunpeng, Hong, Shaodong, Chen, Gang, Zhao, Shen, Chen, Xi, Zhang, Zhonghan, Shen, Jiayi, Xian, Wei, Zhan, Jianhua, Zhao, Yuanyuan, Hou, Xue, Ma, Yuxiang, Zhou, Ting, Zhao, Hongyun, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488117/ https://www.ncbi.nlm.nih.gov/pubmed/30741477 http://dx.doi.org/10.1002/cam4.2018

Ejemplares similares

A modifiable risk factors atlas of lung cancer: A Mendelian randomization study
por: Shen, Jiayi, et al.
Publicado: (2021)

Trends in incidence and associated risk factors of suicide mortality in patients with non‐small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2018)

Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
por: Shen, Jiayi, et al.
Publicado: (2020)

Impact of prior cancer history on the overall survival of younger patients with lung cancer
por: Liu, Jiaqing, et al.
Publicado: (2020)

Genetic Liability to Insomnia and Lung Cancer Risk: A Mendelian Randomization Analysis
por: Shen, Jiayi, et al.
Publicado: (2021)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2018)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Gut Microbiota and Lung Cancer: A Mendelian Randomization Study
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Age at menarche and epithelial ovarian cancer risk: A meta‐analysis and Mendelian randomization study
por: Yang, Huijun, et al.
Publicado: (2019)

Mendelian randomization study of telomere length and lung cancer risk in East Asian population
por: Cao, Xuguang, et al.
Publicado: (2019)

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020)

Depression and prostate cancer risk: A Mendelian randomization study
por: Chen, Xiong, et al.
Publicado: (2020)

Performance of cervical cancer screening and triage strategies among women living with HIV in China
por: Duan, Rufei, et al.
Publicado: (2021)

Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study
por: Zhou, Huaqiang, et al.
Publicado: (2017)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2021)

A large, single‐center, real‐world study of clinicopathological characteristics and treatment in advanced ALK‐positive non‐small‐cell lung cancer
por: Chen, Gang, et al.
Publicado: (2017)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)
por: Zhou, Ting, et al.
Publicado: (2017)

Insulin‐like growth factor‐1 and site‐specific cancers: A Mendelian randomization study
por: Larsson, Susanna C., et al.
Publicado: (2020)

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing
por: Zhang, Yaxiong, et al.
Publicado: (2019)

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2019)

PBX3 hypermethylation in peripheral blood leukocytes predicts better prognosis in colorectal cancer: A propensity score analysis
por: Sun, Hongru, et al.
Publicado: (2019)

The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2017)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
por: Liu, Jiaqing, et al.
Publicado: (2020)

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
por: Zhou, Ting, et al.
Publicado: (2015)

p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
por: Hou, Xue, et al.
Publicado: (2018)

Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
por: Hou, Xue, et al.
Publicado: (2023)

Global, regional and national incidence, mortality and disability‐adjusted life‐years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019
por: Zhang, Wei, et al.
Publicado: (2021)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Significant variations in the cervical cancer screening rate in China by individual‐level and geographical measures of socioeconomic status: a multilevel model analysis of a nationally representative survey dataset
por: Bao, Heling, et al.
Publicado: (2018)

Association of peripheral blood leukocyte KIBRA methylation with gastric cancer risk: a case–control study
por: Zhang, Yan, et al.
Publicado: (2018)

Regional and racial disparity in proximal gastric cancer survival outcomes 1996–2016: Results from SEER and China National Cancer Center database
por: Zhao, Lulu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2n9fved4ru4l9acbcfv51jqt7